Strategies for data analysis: case-control studies

Gilda Piaggio

UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction World Health Organization

Geneva, 23 February 2006

Design of case-control studies: retrospective





Prevalence of disease is fixed by design

	Cases	Controls
Exposed	а	b
Non-exposed	С	d

Fixed margins a+c and b+d

Prevalence of exposure in cases and controls and odds of being exposed

In case-control studies we can calculate:

 Prevalence of exposure in cases and in controls a/(a+c) and b/(b+d)

• The odds ratio to measure association between disease and exposure:

The odds of being exposed for a case is a/c The odds of being exposed for a control is b/d

The odds ratio of exposed vs non-exposed is

 $OR = (a/c)/(b/d) = (a \times d)/(b \times c)$

We cannot calculate the relative risk (RR)

Interpretation of the odds ratio

- If exposure and disease are not associated, OR=1
- If exposure and disease are positively associated, OR>1
- If exposure and disease are negatively associated, OR<1

The OR is a good estimation of the RR if the disease is rare

Strategy for data analysis for case-control studies

- Describe study profile: number of cases and controls, identified and analyzed
- Baseline characteristics of cases and controls
- Crude ORs for different categories of use and risk factors
- ORs for different categories of use and risk factors, adjusting for confounders

Example Oral contraceptives and breast cancer

Lancet 1985; 326:970-972

Study aim was to investigate relation between use of oral contraceptives (OCs) by young women and their risk of breast cancer

Cases: women 20-44 years at initial diagnosis of breast cancer, between Dec 1 1980 and Dec 31 1982, resident in 8 regions of the US, identified from population-based cancer registries.

Controls: women 20-44 years selected during same 25 months as the cases were diagnosed, residents of the 8 regions, selected randomly by telephone calls to households.

Oral contraceptives and breast cancer Study profile: cases



6.4% refused to participate3.7% died or were too ill8.7% miscellaneous reasons

Oral contraceptives and breast cancer Study profile: controls



11.2% refused to participate2.2% moved out3.0% miscellaneous reasons

Oral contraceptives and breast cancer Baseline characteristics of cases and controls

	Cases(%)	Controls(%)		
Age				
2 Ŏ -24	0.7	5.1		
25-29	6.0	8.2		
30-34	18.3	20.8		
35-39	33.5	28.6		
40-44	41.4	37.3		
Family history of breast cancer				
Yes	29.1	18.7		
No	42.3	51.4		
Unknown	28.6	29.9		

Oral contraceptives and breast cancer Baseline characteristics of cases and controls

	Cases(%)	Controls(%)	
Age at first t	erm pregnáncy		
Nulliparous	18.2	18.4	
<20	19.1	22.1	
20-22	23.1	24.7	
23-26	22.3	21.6	
27-29	9.2	7.6	
>29	7.0	4.0	
Parous.			
unknown ag	e 1.1	1.6	
Benign brea	st disease surgerv		
Yes	4.5	2.3	
No	87.2	91.7	
Unknown	8.3	6.0	

Oral contraceptives and breast cancer Results: crude ORs

	Cases	Controls	
Exposed	1701	1662	
Non-exposed	387	403	OR=1.0
All	2088	2065	

Stratification and confounding variables?

Oral contraceptives and breast cancer Results: crude ORs

Age at diagnosis	Cas	ses(%)	Cor	ntrols(%)	
Or selection	N		N		OR
3616611011	IN	users	IN	users	
20-24	15	100.0	106	69.8	-
25-29	126	86.5	169	87.6	0.91
30-34	382	89.3	429	88.1	1.13
35-39	700	86.4	590	85.1	1.11
40-44	865	73.0	771	72.6	1.02
Total	2088	81.5	2065	80.5	1.07

Oral contraceptives and breast cancer Results: adjusting

We need to adjust for factors associated with the risk of breast cancer or with the likelihood of diagnosis:

- Age at diagnosis or selection
- Family history of breast cancer
- Age at first term pregnancy
- History of surgery for benign breast disease
- Frequency of breast examination

Techniques to adjust ORs:

- Logistic regression
- Mantel-Haenszel

Oral contraceptives and breast cancer Results: adjusted ORs

Age at diagnosis	Cases(%)		Controls(%)		
or selection	N	% ever users	N	% ever users	OR(95% CI) (adjusted)
20-24	15	100.0	106	69.8	_
25-29	126	86.5	169	87.6	1.0 (0.5-2.1)
30-34	382	89.3	429	88.1	1.2 (0.7-1.8)
35-39	700	86.4	590	85.1	1.1 (0.8-1.6)
40-44	865	73.0	771	72.6	1.1 (0.9-1.4)
Total	2088	81.5	2065	6 80.5	

Oral contraceptives and breast cancer Conclusions

- There was no significant increase or decrease in the risk of breast cancer for OC users according to
- Age at diagnosis
- Age at first use
- Duration of use
- Use before first term pregnancy

Use of OCs by young women in the US has no effect on the risk of breast cancer before 45 years of age